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External validation of a COPD 
prediction model using population-
based primary care data: a nested 
case-control study
Bright I Nwaru1,2, Colin R Simpson1, Aziz Sheikh1,3 & Daniel Kotz1,3,4
Emerging models for predicting risk of chronic obstructive pulmonary disease (COPD) require external 
validation in order to assess their clinical value. We validated a previous model for predicting new 
onset COPD in a different database. We randomly drew 38,597 case-control pairs (total N = 77,194) of 
individuals aged ≥35 years and matched for sex, age, and general practice from the United Kingdom 
Clinical Practice Research Datalink database. We assessed accuracy of the model to discriminate 
between COPD cases and non-cases by calculating area under the receiver operator characteristic 
(ROCAUC) for the prediction scores. Analogous to the development model, ever smoking (OR 6.70; 95%CI 
6.41–6.99), prior asthma (OR 6.43; 95%CI 5.85–7.07), and higher socioeconomic deprivation (OR 2.90; 
95%CI 2.72–3.09 for highest vs. lowest quintile) increased the risk of COPD. The validated prediction 
scores ranged from 0–5.71 (ROCAUC 0.66; 95%CI 0.65–0.66) for males and 0–5.95 (ROCAUC 0.71; 95%CI 
0.70–0.71) for females. We have confirmed that smoking, prior asthma, and socioeconomic deprivation 
are key risk factors for new onset COPD. Our model seems externally valid at identifying patients at 
risk of developing COPD. An impact assessment now needs to be undertaken to assess whether this 
prediction model can be applied in clinical care settings.
The burden of chronic obstructive pulmonary disease (COPD) has been rising, now representing one of the lead-
ing causes of morbidity and mortality worldwide1. Whilst estimates of disease burden have primarily come from 
developed countries, the prevalence appears to be rising in developing countries as well, and the resultant mor-
tality is projected to rise by 30% in the next decade2. In the United States (US), over 12 million adults have COPD, 
representing the third leading cause of death3; it is the second most common cause of emergency hospitalisation 
in the United Kingdom (UK)4–6.
Whilst some studies have evaluated algorithms to identify individuals with established COPD7–9, the rate of 
undiagnosed disease remains high10, occurring in one out of eight people over the age of 35 years6. There is a 
paucity of studies that have developed hands-on tools that enable early identification of individuals9 at-risk of 
future COPD. Our ability to construct models that will enhance identifying individuals at risk well before dis-
ease onset will provide the opportunity for developing key strategies for prevention11. Using the Primary Care 
Clinical Informatics Unit (PCCIU) general practice (GP) database, we developed and internally validated the first 
risk prediction model for early detection of incident COPD, which simultaneously took into account a range of 
known risk factors, including smoking, age, sex, prior asthma, and socio-economic status11. A more recent study 
utilised the UK Clinical Practice Research Datalink (CPRD) database to similarly develop and validate a COPD 
prediction model, deriving comparable predictive values as our previous study12. However, it is important, prior 
to using these risk scoring systems in clinical practice that they are externally validated in entirely different data-
sets of comparable populations.
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In the current study, we therefore aimed to externally validate our previously developed prediction model 
(developed using the PCCUI GP database) using a different database (i.e. the CPRD GP database). The current 
work is the first to externally validate a COPD prediction algorithm for early detection of individuals at-risk of 
future COPD in an entirely different database but comparable population.
Results
Background characteristics of the study population. Overall, majority of the patients had smoked 
at some point, but the proportion of smokers was higher in COPD cases (n = 33,269; 86%) than in controls 
(n = 19,908; 52%), regardless of whether the CPRD smoking codes or the PCCIU codes were used (Table 1). The 
proportion of those with prior asthma was up to n = 13,161, 17% (cases n = 10,210, 27%; controls n = 2,951, 7%). 
A higher proportion of cases was more deprived than controls as measured by the Index of Multiple Deprivation 
(IMD) quintile (Table 1).
Associations between risk factors and COPD. In unadjusted and adjusted (i.e. simultaneous adjust-
ment for all factors) models, ever smoking was associated with a seven-fold increased odds of COPD (Table 2). 
Prior asthma was associated with an increased risk of COPD: adjusted OR for prior asthma was 5.04 (95% CI 
4.77–5.33). Compared to the least deprived IMD quintile, those in the more deprived IMD quintiles were increas-
ingly at higher risk of COPD (Table 2). The estimates for smoking and prior asthma were similar in magnitude 
and direction when either of the codes from CRPD and PCCIU data were used in the analyses (data not shown).
Validation of COPD prognostic index. Table 3 presents the validated decile prognostic scores when the 
scores derived from the development models based on the PCCIU data were applied to the CPRD data. The scores 
were derived for males and females separately and ranged from 0 (lowest) to 5.71 (highest) for males and 0 to 
5.95 for females. Some deciles did not have corresponding prognostic scores, an indication that the scores were 
not normally distributed. The accuracy of the validated prediction model in discriminating between COPD and 
non-COPD patients was ROCAUC = 0.66 (95% CI 0.65–0.66) for males and ROCAUC = 0.71 (95% CI 0.70–0.71) for 
Characteristic
All N = 77,002 
n (%)
COPD Cases 
n = 38,511 n (%)
Controls 
n = 38,491 n (%)
Smoking status
 Never smoker 23,825 (30.9) 5,242 (13.6) 18,583 (48.3)
 Ever smoker 53,177 (69.1) 33,269 (86.4) 19,908 (51.7)
Previous asthma prior to diagnosis of COPD
 No 63,841 (82.9) 28,301 (73.5) 35,540 (92.3)
 Yes 13,161 (17.1) 10,210 (26.5) 2,951 (7.7)
IMD Quintiles
 1st Quintile (least deprived) 13,470 (17.5) 5,801 (15.1) 7,669 (19.9)
 2nd Quintile 16,788 (21.8) 7,814 (20.3) 8,974 (23.3)
 3rd Quintile 15,223 (19.8) 7,446 (19.3) 7,777 (20.2)
 4th Quintile 16,291 (21.1) 8,794 (22.8) 7,497 (19.5)
 5th Quintile (most deprived) 15,230 (19.8) 8,656 (22.5) 6,574 (17.1)
Table 1.  Participants’ baseline characteristics by COPD cases and controls. COPD = chronic obstructive 
pulmonary disease. CPRD = Clinical Practice Research Datalink general practice database.
Unadjusted OR (95% CI) 
N = 77,002
Adjusted1 OR (95% CI) 
N = 77,002
Smoking status
 Never smoker 1 1
 Ever smoker 7.01 (6.70–7.33) 7.21 (5.88–7.57)
Previous asthma prior to diagnosis of COPD 
 No 1 1
 Yes 4.52 (4.31–4.74) 5.04 (4.77–5.33)
Index of Multiple Deprivation Quintiles
 1st Quintile (least deprived) 1 1
 2nd Quintile 1.34 (1.27–1.41) 1.23 (1.16–1.31)
 3rd Quintile 1.64 (1.55–1.73) 1.47 (1.37–1.57)
 4th Quintile 2.20 (2.07–2.32) 1.81 (1.68–1.94)
 5th Quintile (most deprived) 2.90 (2.72–3.09) 2.17 (2.00–2.34)
Table 2.  Unadjusted and adjusted associations between risk factors and diagnosis of COPD: Odds ratio 
(OR), 95% confidence interval (95% CI). COPD = chronic obstructive pulmonary disease. CPRD = Clinical 
Practice Research Datalink general practice database. IMD = Index of Multiple Deprivation.
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females (Table 3). The ROC curves for the validated scores are shown in Fig. 1 and the sensitivity and specificity 
values for the various cut points on the prognostic scores are shown in Supplementary File 4.
COPD prognostic scores derived from the CPRD data. Table 4 presents the prognostic scores derived 
solely from the CPRD data. The scores ranged from 0 to 4.37. The corresponding ROCAUC for assessing the accu-
racy of the model was 0.74 (95% CI 0.73–0.74). The ROC curves are shown in Figure S1 of Supplementary File 5. 
The prognostic scores were similar when either of the smoking and prior asthma codes from CRPD and PCCIU 
data were used in the analyses (data not shown).
Discussion
In this first ever external validation exercise of a COPD prediction model using the CPRD database, we have 
found similar prediction estimates as those derived from the PCCIU database derived based model, both in the 
magnitude and direction of effect. Whilst the prognostic scores based on the development model ranged from 
0 to 7.50, similarly for males and females, the scores from the current validation study ranged from 0 to 5.71 for 
males and 0 to 5.95 for females. Similarly, whilst we observed some small differences in the associations between 
smoking, prior asthma, and deprivation quintiles and the risk of COPD, these were largely in the same direction 
of impact as expected. As expected, the accuracy of the models as measured by the ROCAUC were somewhat lower 
Range of values for deciles of PI scores Area under ROC 
curve (95% CI)1 (lowest) 2 3 4 5 6 7 8 9 10 (highest)
Prognostic scores
 Males 0.00–0.00 0.61–1.41 1.42–1.91 — 1.92–2.52 — 2.53–3.31 — 3.32–4.49 4.50–5.71 0.66 (0.65– 0.66)
 Females 0.00–0.00 0.01–0.45 0.46–1.50 1.51–2.26 — 2.27–2.71 2.72–3.73 3.74–3.76 3.77–4.93 4.94–5.95 0.71 (0.70–0.71)
Table 3.  Validation of COPD prognostic scores derived from the PCCIU data using the CPRD data. 
COPD = chronic obstructive pulmonary disease. PCCIU = Primary Care Clinical Informatics Unit general 
practice database. CPRD = Clinical Practice Research Datalink general practice database. ROC = receiver 
operating characteristics. Some deciles did not have corresponding prognostic scores, an indication that the 
scores were not normally distributed.
Figure 1. ROC curves for the validated prognostic scores, for males (top) and females (bottom): the 
prediction model developed using the PCCIU data was applied to the CPRD data. 
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in this validation study (males 0.66, females 0.71) compared to the development study (males 0.83, females 0.85); 
nonetheless, these estimates still have the potential to be very useful in clinical practice.
The CPRD database is a well-characterised population-based primary care database and is one of the best 
validated large primary care research databases in the world13,14. With sufficient sample size and power, we have 
– for the first time –validated a COPD prediction score in a different dataset, obtaining similar risk factors and 
analogous accuracy estimates to discriminate COPD cases from non-cases compared to the measures derived 
from the prediction development study11. In comparison to the prediction development study using the PCCIU 
database11, the coding for smoking and asthma was more complete in the current study using the CPRD data. No 
differences were however seen when either of the CPRD- and PCCIU-derived codes were used.
A limitation of this study is that it was based on a matched case-control design but nested in a longitudi-
nal population cohort (with estimation of the conditional odds ratios of the influence of the risk factors on the 
development of COPD), whereas the prediction development study was based on a follow-up cohort study (with 
estimation of the hazard ratios of the influence of the risk factors on a 10-year risk of COPD). Nevertheless, the 
estimates of associations between the various risk factors and the development of COPD were both in the direc-
tion and magnitude comparable between the validation and prediction development studies. Although the meas-
ures of accuracy (using the ROCAUC) of the prediction model in discriminating between COPD cases and controls 
were slightly lower in the current study compared to the prediction development study, the differences were as 
expected, given previous evidence in this respect, i.e. accuracy measures of prediction models more often are seen 
to be lower in an externally validated dataset compared to estimates derived from the prediction development 
dataset15. This work has therefore served to confirm the importance of undertaking external validation studies. 
Further limitation of our work is that, spirometry measures, which are the gold standard for diagnosing COPD, 
are not routinely recorded in the GP databases, hence we could not utilise them in this study. Similarly, pack-years 
of smoking, a desired exposure indicator to assess the causal impact of smoking, is not routinely collected in GP 
databases, hence we did not consider it in this study.
As the first validation of a risk score for predicting the development of COPD in a different external database, 
there is no applicable previous study to compare the results. Overall, the risk estimates for the studied risk factors 
(smoking, prior asthma, and socioeconomic status) were comparable to the estimates from the prediction model 
development study. Whilst a recent study using CPRD undertook an external validation of the prediction scores, 
the validation work was done within the same database: the authors split the original data into two (develop-
ment and validation samples) datasets, using one dataset to develop the prediction scores and the second dataset 
comprising of 20 CPRD general practices to validate the scores12. External validation of prediction models aims 
to assess the generalisability of the derived model in an appropriate similar patient population, but in a different 
context; this work therefore needs to be undertaken in a new dataset15–17.
In comparison to the recent study using CPRD database to develop and validate a prediction model12, the 
risk estimates with regards to smoking and asthma, although in the same direction as observed in the current 
study, somewhat differed in magnitude, possibly as different definitions were used between the two studies. In the 
current study we defined smoking as “ever smoking” while the previous study differentiated between former and 
current smoking12. Another difference between the current study and the previous CPRD study was that variables 
included in the final model differed, which may explain the differences observed: whilst the final model in the 
current study included smoking status, prior asthma, and IMD, the previous study included smoking status, prior 
asthma, salbutamol prescription, and lower respiratory tract infections. Further difference relates to the time cov-
erage of participants’ enrolment into the two studies: the current study included participants between 1992 and 
2012, whereas the previous study covered between 2000 and 2006. The UK Quality and Outcomes Framework 
(QOF) for COPD started in 2004, at which point the coding of COPD improved5,6. However, since both studies 
contained data both prior to and after the start of the QOF, we believe the time coverage of studies may not have 
substantially influenced the observed variations in results.
Other previous studies from the US7,8 and Denmark9 developed prediction algorithms aimed at identifying 
COPD patients with already established disease. They were also based on secondary care data, such as admin-
istrative claims data, outpatient pharmacy data, and hospital admissions data, hence contrast the current study, 
which used population-based primary care to validate prediction scores aimed at identifying at-risk individuals 
before the onset of disease.
As the incidence of COPD and mortality continues to rise globally, our ability to detect cases before they man-
ifest is crucial6,11,12. The current COPD prediction model, now externally validated in a different dataset, but com-
parable population, provides a convincing opportunity for evaluating its usefulness and applicability in clinical 
care settings for identifying individuals at high risk of developing the disease18. The current validation confirms 
the importance of smoking history, prior asthma, and socioeconomic status19, which in combination provide a 
composite prediction score to accurately identify individuals at different risk categories (based on the our pre-
diction model, low category had risk scores ≤ 6, medium risk score of 7, and high risk score 8–10) of developing 
COPD11. The current study is the first to externally validate a COPD prediction score. Whilst emerging COPD 
Range of values for deciles of prognostic scores Area under ROC 
curve (95% CI)1 (lowest) 2 3 4 5 6 7 8 9 10 (highest)
Prognostic scores 0.00–.21 0.22–0.59 0.60–1.98 1.99–2.19 — 2.20–2.36 2.37–2.57 2.58–2.75 2.76–3.80 3.81–4.37 0.74 (0.73–0.74)
Table 4.  Prognostic scores derived from the CPRD data. CPRD = Clinical Practice Research Datalink 
general practice database. ROC = receiver operating characteristic.
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prediction models from other contexts also need to be externally validated in different datasets, we believe that 
the risk scores derived from the current external validation exercise can now be assessed whether it can applied 
in clinical settings with a concurrent impact assessment of its performance.
In conclusion, using a large internationally respected database, we have – for the first time – validated a COPD 
prediction model for identifying at-risk individuals prior to the onset of disease in a different database but com-
parable population, with acceptable accuracy at discriminating between COPD cases and non-COPD cases. Key 
predictors of onset of COPD include smoking, prior asthma, and socioeconomic status. Consideration now needs 
to be made, with a concurrent impact assessment on performance, on whether the validated risk score is useful 
and can be readily applied in clinical practice for identifying those at risk of developing COPD.
Methods
Study population. The CPRD database is a validated computerised, anonymised and longitudinal primary 
care database, considered by many as the gold standard of routine clinical research data (www.cprd.com)13,14. It is 
jointly funded by the UK National Health Service (NHS) and the Medicines and Healthcare products Regulatory 
Agency (MHRA). Data are linkable to other healthcare and social care data sources, and are regularly used to 
conduct both observational and interventional research in the UK. Presently the database comprises around 14 
million patients derived from 660 primary care practices across the UK13,14. We received access to CPRD under 
licence from the Medical Research Council (MRC). The CPRD Group has obtained ethical approval from a Multi-
centre Research Ethics Committee for all purely observational research using CPRD database. The protocol of 
the current study was approved by the Independent Scientific Advisory Committee of CPRD (protocol number 
10_084 R). All the study methods were performed in accordance with the relevant guidelines and regulations and 
in accordance with best scientific practices.
We extracted a random sample from the CPRD of COPD cases and controls aged ≥ 35 years: index cases and 
their corresponding controls were matched at a ratio of 1:1 on GP practice, sex, and year of birth (within two 
years). Cases comprised of individuals with first recorded COPD diagnosis and who were followed for at least 
five years prior to the index date (i.e., date of drawing the sample). Identification of cases and controls and defi-
nition of other study variables were based on the Read Clinical Classification System, a standard coding system 
produced for clinicians in primary care and which is used for most primary care electronic patient records in the 
UK (a complete list of Read codes used for this study is given in Supplementary File 1). A control must have been 
registered at the same practice at the time of the index date of the corresponding case and should have had at least 
five years of follow-up in the same practice prior to the index date of the case. The index date for the controls was 
the date of the recording of COPD for the corresponding matched case.
In total, we sampled 38,597 case-control pairs (total N = 77,194). This was the maximum number of allowable 
patients extracted under the Medical Research Council license. Of these, 188 (84 [0.22%] cases and 104 con-
trols [0.27%]) had missing data for IMD, hence were excluded from analyses. The IMD is the UK government’s 
measure to assess household’s socio-economic status based on the level of deprivation of an area (http://census.
ukdataservice.ac.uk/get-data/related/deprivation). Two controls without ID numbers and their corresponding 
cases were further excluded, resulting in a total of 77,002 (38,511 cases and 38,491 controls) as the final sample 
for analyses.
Assessment and definition of risk factors. From CPRD, we extracted the same variables used in the 
PCCIU data to develop the prediction model (i.e., smoking, prior asthma, and IMD); the current study sample 
was matched for age and sex. Smoking status was categorised into “never smoker” (i.e., patients recorded as 
“non-smoker” at any time and no coding as “smoker” or “ex-smoker” at any other time) or “ever smoker” (i.e., 
patients recorded as “smoker” or “ex-smoker” at any time); “never smoker” was the reference category. Prior 
asthma was categorised as “no” or “yes”; “no” was the reference category. As the study was nested within a longi-
tudinal cohort, the timing of occurrence of asthma was determined and we ensured that only asthma cases occur-
ring prior to COPD were defined as positive. IMD was categorised into quintiles (quintile 1 as least deprived and 
quintile 5 as most deprived); quintile 1 was the reference category.
We observed some differences in coding of smoking and asthma between the CPRD and PCCIU data: in 
comparison to the codes in PCCIU, CPRD comprised of four extra codes for smoking status and 15 extra codes 
for asthma (see supplementary File 1). This resulted in about 0.5% extra ever smokers and about 12% extra prior 
asthma cases by using CPRD codes compared with PCCIU codes. The Read code, H33.00 (Asthma), contributed 
to most (85%) of the extra asthma cases in CPRD. Whilst we used CPRD-derived codes throughout the validation 
exercise, we also separately analysed PCCIU-derived codes to assess whether there were any differences between 
the two codes in terms of the direction and magnitude of the prediction scores.
Statistical analysis. The Stata codes for data preparation and analyses are presented in Supplementary Files 
2 and 3, respectively. For descriptive analysis we calculated the frequencies of participants’ background char-
acteristics by cases and controls. Assessment of the associations between the risk factors and the risk of COPD 
was performed by calculating the unadjusted and adjusted risk estimates using conditional logistic regression. 
These estimates are reported as odds ratio (OR) and accompanied by their 95% confidence intervals (95% CI). It 
should be noted that while the development model was based on a longitudinal data (hence modelling using Cox 
regression), the current validation work is based on a matched case-control study (hence the calculation using 
conditional logistic regression).
A two-part approach was used to undertake the external validation of the prediction model. First, the risk 
scores derived from the prediction model (based on coefficients across categories of the variables included in the 
fully adjusted Cox regression model)11 were applied to the corresponding categories of each predictor in the val-
idation model, thus deriving the prognostic scores for each individual in the validation model of the CPRD data; 
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this was done separately for males and females. The resulting risk scores were then divided into 10 risk categories 
(deciles). The approach is described in Table 5.
For example, a 60-year-old male ever smoker, with IMD level 3 and no previous history of asthma would yield 
a prognostic index (PI) of 5.0 (risk category 9 = high risk of future COPD); a 40-year-old female never smoker, 
with IMD 3 and a previous history of asthma would yield a PI of 2.2 (risk category 3 = low risk of future COPD).
In the second part of the validation model, the prognostic scores for each individual was derived solely based 
on the CPRD data using the method applied in the model development: i.e., calculation of the risk scores as the 
sum of the regression coefficients across the different categories of the variables in the fully adjusted conditional 
logistic regression model. Due to the CPRD validation dataset being matched for sex and age, the scores were 
calculated for males and females combined and not separated by sex. The resultant risk scores were then divided 
into deciles. Illustratively, given the beta regression coefficients for the categories of the different factors as β, 
calculation of the risk scores was given as follows:
= β + β + β + β
+ β + β
⁎ ⁎ ⁎
⁎ ⁎ ⁎
Prognosticscore Smoking IMD2 IMD3
IMD4 IMD5 Asthma
(smoking) (IMD2) (IMD) (IMD)
(IMD) (asthma)
Where β (smoking)*Smoking is the coefficient for a smoker vs never smoker as the reference; β (IMD2)*IMD2 is the 
coefficient for an individual in the second quintile of IMD to β (IMD)*IMD5 for an individual in the highest quintile 
of IMD vs firs quintile as the reference; and β (asthma)*Asthma for an individual with asthma vs non-asthma as the 
reference.
For each validation model, the accuracy of the prognostic scores in discriminating between COPD and 
non-COPD patients was estimated by calculating the area under the receiver operator characteristic curve 
(ROCAUC) for all values of the scores.
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